

# Diversity and equity in pharmacoepidemiological studies

1 OCTOBER	
9.00-10.00	Arrival, registration, light breakfast and poster mounting
10.00-10.10	Welcome by DSFE chair Mette Bliddal
10.10- 11.40	SESSION I: MEDICATION ADHERENCE
	Chairs: Lina Steinrud Mørch, the Danish Cancer Institute & Kristine Højgaard Allin, Aalborg University
10.10-10.55	Tracking treatment over time: Methods and applications in oncology
	Jennifer Lund, University of North Carolina at Chapel Hill, USA
10.55-11.25	Adherence to adjuvant endocrine therapy in women with breast cancer Kirsten Marie Woolpert, Aarhus University, Denmark
11.25-11.40	Oral abstract presentation: Likelihood and predictors for discontinuing semaglutide injection for weight loss: Nationwide population-based study of the first 51,790 users in Denmark
	Aurélie Mailhac, Aarhus University, Denmark
11.40-12.00	Coffee break
12 00-12 30	ANNIVERSARY DSEE I ECTURE

Chair: Signe Sørup, Aarhus University Hospital DSFE founder Jesper Hallas, previous DSFE chair Anton Pottegaard and DSFE chair Mette Bliddal

# 12.30-13.00 General Assembly (for DSFE members only)

Chair: Reimar W. Thomsen, Aarhus University

13.00-13.45 Lunch







# 13.45-15.30 SESSION II: METHODS IN PHARMACOEPIDEMIOLOGY

Chairs: Jesper Hallas & Helene Kildegaard, University of Southern Denmark

13.45-14.30 Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA): A new approach to studying social disparities in drug use

George Leckie, University of Bristol, United Kingdom

14.30-15.15 **How to generate realistic, non-personal synthetic health data?** 

Martin Bøgsted, Aalborg University, Denmark

15.15-15.30 **Oral abstract presentation: The ICH E9(R1) Estimand Framework in the** 

context of Real-World Data and Observational Studies

Lotte Husemoen, Novo Nordisk, Copenhagen, Denmark

### 15.30-16.00 Coffee and check-in

# 16.00-17.30 Moderated poster-walks in groups & pre-dinner drinks

## 16.00-16.30 Walk 1: Pharmacoepidemiological methods

Chairs: Tea Skaaby, LEO Pharma & Helene Kildegaard, University of Southern Denmark

Walk 2: Cancer and type 2 diabetes

Chairs: Lotte Husemoen, Novo Nordisk & Kristine Højgaard Allin, Aalborg University

# 16.40-17.20 Walk 3: Diseases and drugs in later life

Chairs: Cathrine Hjorth, Aarhus University & Marie Lund, Bispebjerg & Frederiksberg University Hospital

# Walk 4: Health in early life, childhood and adolescence

Chairs: Signe Sørup, Aarhus University Hospital & Nils Skajaa, Novo Nordisk *Please find detailed poster information on the last page of the program* 

18.30 **Dinner** 







# 2 OCTOBER

7.00 10.30	Chairs: Deirdre Cronin-Fenton, Aarhus University & Nils Skajaa, Novo Nordisk
9.00-9.45	Perinatal pharmacotherapy during pregnancy and lactation Hedvig Nordeng, University of Oslo, Norway
9.45-10.15	Using real-world data to study LDL reduction in older people Marie Lund, Bispebjerg & Frederiksberg University Hospital, Denmark
10.15-10.30	Oral abstract presentation: GLP-1 agonists as potential neuromodulators in development of Parkinsons's disease: a nationwide cohort study
	Mads Gamborg, the Danish Cancer Institute, Copenhagen, Denmark
10.30-11.15	Coffee break and networking walk
11.15-13.00	SESSION IV: PRECISION MEDICINE
	Chairs: Tariq Halasa, Novo Nordisk & Tea Skaaby, LEO Pharma
11.15-12.00	Development of anti-drug antibodies to TNF inhibitors in patients with Crohn's disease
	Aleksejs Sazonovs, Aalborg University, Denmark
12.00-12.45	Leveraging AI in pharmacology and pharmacogenomics
	Roxana Daneshjou, Stanford University, USA
12.45-13.00	Oral abstract presentation: Acute cardiovascular effects associated with the use of prescription medications: A Danish nationwide screening study
	Saad Hanif Abbasi, University of Southern Denmark, Odense, Denmark
13.00-13.45	Lunch
13.45-14.00	Goodbye and award for best oral presentation and poster presentation based on submitted abstracts







#### POSTER INFORMATION

\_\_\_\_\_\_

#### WALK 1: PHARMACOEPIDEMIOLOGICAL METHODS

Poster 1: Methods applied to assess real-world effectiveness of drugs: A scoping review

Benedikte Irene von Osmanski, Signum Life Science

Poster 2: A Bayesian joint modeling approach to estimate drug interactions with tamoxifen in premenopausal breast cancer patients

Kirsten M. Woolpert, Aarhus University

**Poster 3: A common data model for pharmacoepidemiological studies in Denmark, Norway and Sweden**Peter B Jensen, University of Southern Denmark

### **WALK 2: CANCER AND TYPE 2 DIABETES**

Poster 7: Breast cancer incidence by subtypes - a Danish register-based study from 2012 to 2022 Cathrine Tipsmark, Signum Life Science, Copenhagen

Poster 8: Association of educational level with clinical presentation and pharmacological treatment in 10,020 individuals with recently diagnosed type 2 diabetes

Frederik PB Kristensen, Aarhus University

Poster 9: Pre-diagnostic use of menopausal hormone therapy and colorectal cancer recurrence and mortality: a Danish population-based cohort study

Julie A. Schmidt, Aarhus University

#### WALK 3: DISEASES AND DRUGS IN LATER LIFE

Poster 4: Treatment of erectile dysfunction after radical prostatectomy

Signe B Larsen, Copenhagen University Hospital - Rigshospitalet

Poster 5: Opioids and dementia: nationwide Danish population-based study

Nelsan Pourhadi, Copenhagen University Hospital - Rigshospitalet

Poster 6: Changes in psychotropic drug use among Danish care home residents during and after the COVID-19 pandemic

Hanin Harbi, University of Southern Denmark

### WALK 4: HEALTH IN EARLY LIFE, CHILDHOOD AND ADOLESCENCE

Poster 10: A population-based observational study of determinants of varicella vaccination in the private market in Denmark

Anne Cathrine Falch-Jørgensen, Signum Life Science

Poster 11: Prenatal exposure to antifungal agents and risk of immune-mediated inflammatory diseases Christian Sørensen, Aalborg University

Poster 12: Eating disorders in children, adolescents, and young adults during and after the COVID-19 pandemic

Heidi E Sonne, University of Copenhagen

Poster 13: Impact of pre- and postnatal maternal inflammatory bowel disease status on offspring's risk of inflammatory bowel disease: a population-based cohort study
Linéa Bonfils, Aalborg University



